Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

← catalyst calendar

NCT07069738 · readout ≤ 1,199 d

Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.

Phase

Not applicable

Status

Recruiting

Study type

Interventional

Design

Randomized · Single · Treatment

Enrollment

850estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-10-22

actual

When the study began enrolling

Primary completion

Nov 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Nov 2029

estimated

The whole study's end, after follow-up

First posted

2025-07-17

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Heart Failure - NYHA II - IV

Interventions

Device: CRT-D with a Quadripolar LV lead
Device: CRT-D with INGEVITY+ pace/sense lead

Primary outcomes

what the primary-completion date above is the date OF

Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.

measured Through study completion, up to maximum of 5 years

System-related complication-free rate

measured 12 months

Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed